About: Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

clinical trial

Attributes	Values
rdf:type	Item
description	clinical trial (en) ensayu clínicu (ast) klinisch onderzoek (nl) клінічне випробування (uk)
rdfs:label	Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (en) Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (nl)
skos:prefLabel	Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (en) Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (nl)
name	Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (en) Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (nl)
title	wds:Q79111786-347A1B3C-8AD7-411A-8517-5FF1D58CBBB8
title	An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 in Subjects With Locally Advanced or Metastatic Solid Tumors (en)
end time	wds:Q79111786-AC33F162-DA72-4CDD-9ABF-B338C61FA504
end time	2022-12-02 00:00:00Z (xsd:dateTime)
instance of	wds:Q79111786-E1585CEB-8C3D-4075-A1AF-DD47D7DC6FAD
instance of	clinical trial
start time	wds:Q79111786-B1998ED8-15D4-48B0-B940-E8C26556CBF8
start time	2019-12-10 00:00:00Z (xsd:dateTime)
country	wds:Q79111786-C2903B5A-2A91-4D5F-A735-D9F4B674BA0B
country	United States of America
main subject	wds:Q79111786-3EA6F181-61C4-4FA8-9743-4A29304628BA
main subject	renal pelvis and ureter transitional cell cancer
research intervention	wds:Q79111786-13C4784C-904F-4A74-836E-5A94C248522C
research intervention	pembrolizumab
minimum age	wds:Q79111786-455D61E8-D13F-4EBC-8703-71F6A3C311CC
minimum age	18 (xsd:decimal)
medical condition	wds:Q79111786-45B1AE4A-5EA8-4329-B167-2EA9557CC705 wds:Q79111786-88C2D4A0-8543-4265-8D9E-6BCDD10C5F90
medical condition	melanoma carcinoma
number of participants	wds:Q79111786-0AFE11F7-E83D-4A27-A040-163B7F12B219
number of participants	150 (xsd:decimal)
study type	wds:Q79111786-B385B732-7342-42BC-BDF2-737EC3AD221E
study type	interventional study
ClinicalTrials.gov ID	wds:Q79111786-A447C0E4-79FA-45D7-B32F-C225F3BA6F7C
ClinicalTrials.gov ID	NCT04198766
clinical trial phase	wds:Q79111786-AC54A07C-78ED-479A-9C74-AA6F582AD98C
clinical trial phase	phase I clinical trial
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q79111786

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software